课题基金 / 基金详情

Determining if implementation of the haptoglobin phenotype biomarker should be tested in type 2 diabetes treatment planning to prevent cardiovascular disease: a biostatistical analysis, a cost-effectiveness analysis, and a patient priority analysis

Determining if implementation of the haptoglobin phenotype biomarker should be tested in type 2 diabetes treatment planning to prevent cardiovascular disease: a biostatistical analysis, a cost-effectiveness analysis, and a patient priority analysis
确定是否应在 2 型糖尿病治疗计划中测试触珠蛋白表型生物标志物的实施以预防心血管疾病：生物统计分析、成本效益分析和患者优先分析
批准号：
458643
负责人：
Carew Allie S
金额：
$7.65万
依托单位：
Dalhousie University (Nova Scotia)
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-11-01 至 2024-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=458643&lang=en
关键词：
Cardiometabolic Disease Clinical Epidemiology Cost-Effectiveness Analysis Glycemic Control Haptoglobin Phenotype Patient-Oriented Research Personalized Medicine Secondary Analysis

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
People with type 2 diabetes have a higher risk of heart disease compared to people without type 2 diabetes. However, studies of strict blood sugar control (aiming for near-normal blood sugar levels) among people with type 2 diabetes have not prevented hea
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金